List of Nuvigil drug patents

Nuvigil is owned by Cephalon.

Nuvigil contains Armodafinil.

Nuvigil has a total of 4 drug patents out of which 0 drug patents have expired.

Nuvigil was authorised for market use on 15 June, 2007.

Nuvigil is available in tablet;oral dosage forms.

The generics of Nuvigil are possible to be released after 18 June, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil
Nov, 2023

(5 months from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(11 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Jun, 2024

(1 year, 10 days from now)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's patent expiration?
More Information on Dosage

NUVIGIL family patents

17

United States

8

China

8

European Union

6

Hong Kong

5

Japan

5

Spain

4

Canada

4

New Zealand

4

Australia

3

Korea, Republic of

3

Brazil

3

Taiwan

3

Malaysia

3

Argentina

3

Mexico

3

Norway

3

South Africa

3

Israel

2

France

2

Chile

2

Poland

2

Slovenia

2

Ukraine

2

Iceland

2

Germany

2

Denmark

EA

2

EA

2

Austria

2

Portugal

2

Cyprus

1

Egypt

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic